The objective of the next ISTH Academy webinar, titled, Thrombotic Thrombocytopenic Purpura (TTP): New Insights in Pathogenesis and Treatment Modalities, is to thoroughly cover how to treat patients with TTP along with the ways in which new molecular and biochemical discoveries could translate into new treatment options.
The presentation will address the history of thrombotic thrombocytopenic purpura (TTP) and the discovery of the metalloprotease ADAMTS13 which plays a key role in regulating the size of multimeric von Willebrand factor. A severe deficiency of ADAMTS13, either hereditary or acquired due to inactivating autoantibodies, is an important pathogenetic factor for the onset of TTP. Some additional triggering mechanisms may be necessary to bring about acute disease both in hereditary as well as in autoantibody mediated ADAMTS13 deficiency.
After a brief discussion of the standard treatment, the presentation will address novel and emerging therapies for patients with acquired TTP and will include approaches to therapies currently being studied in clinical trials as well as novel approaches that may soon be entering clinical study. At the end of the presentation, participants will have a better understanding of these targeted approaches to therapy and their mechanisms of action. A better knowledge of these targeted therapies are essential going forward as they begin to play a greater role in the treatment of patients with acquired TTP.